{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T09:20:58Z","timestamp":1791105658684,"version":"4.1.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2000,9,1]],"date-time":"2000-09-01T00:00:00Z","timestamp":967766400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Experimental Neurology"],"published-print":{"date-parts":[[2000,9]]},"DOI":"10.1006\/exnr.2000.7444","type":"journal-article","created":{"date-parts":[[2002,9,16]],"date-time":"2002-09-16T11:46:56Z","timestamp":1032176816000},"page":"136-142","source":"Crossref","is-referenced-by-count":106,"title":["Antiparkinsonian Actions of Ifenprodil in the MPTP-Lesioned Marmoset Model of Parkinson's Disease"],"prefix":"10.1006","volume":"165","author":[{"given":"J.E.","family":"Nash","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.H.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.P.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Peggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"McGuire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Maneuf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Hille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Brotchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.R.","family":"Crossman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1006\/exnr.2000.7444_RF1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1471-4159.1991.tb02096.x","article-title":"[3H]MK-801 binding to N-methyl-d-aspartate receptors solubilised from rat brain: Effect of glycine site ligands, polyamines, ifenprodil and desipramine","volume":"57","author":"Bakker","year":"1991","journal-title":"J. Neurochem."},{"key":"10.1006\/exnr.2000.7444_RF2","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0022-510X(90)90225-C","article-title":"The MPTP model: Versatile contributions to the treatment of idiopathic Parkinson's disease","volume":"97","author":"Bloem","year":"1990","journal-title":"J. Neurol. Sci."},{"key":"10.1006\/exnr.2000.7444_RF3","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0079-6123(08)61342-4","article-title":"Chemical signalling in the globus pallidus in parkinsonian","volume":"99","author":"Brotchie","year":"1993","journal-title":"Prog. Brain Res."},{"key":"10.1006\/exnr.2000.7444_RF4","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/00019052-199708000-00010","article-title":"Novel approaches to the symptomatic treatment of parkinsonian syndromes: Alternatives and adjuncts to dopamine replacement","volume":"10","author":"Brotchie","year":"1997","journal-title":"Curr. Opin. Neurol."},{"key":"10.1006\/exnr.2000.7444_RF5","first-page":"41","article-title":"Opioid peptide precursor expression in animal models of dystonia secondary to dopamine-replacement therapy in Parkinson's disease","volume":"78","author":"Brotchie","year":"1998","journal-title":"Adv. Neurol."},{"key":"10.1006\/exnr.2000.7444_RF6","first-page":"433","article-title":"Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson's disease","volume":"166","author":"Calabresi","year":"1993","journal-title":"Brain"},{"key":"10.1006\/exnr.2000.7444_RF7","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/BF01258633","article-title":"The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice","volume":"75","author":"Carlsson","year":"1989","journal-title":"J. Neural Transm."},{"key":"10.1006\/exnr.2000.7444_RF8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/BF01255820","article-title":"Dramatic synergism between MK-801 and clonidine with respect to locomotor stimulatory effect in monoamine-depleted mice","volume":"77","author":"Carlsson","year":"1989","journal-title":"J. Neural Transm."},{"key":"10.1006\/exnr.2000.7444_RF9","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0091-3057(90)90123-Y","article-title":"Interfering with glutamatergic transmission by means of NMDA antagonist administration discloses the locomotor stimulatory potential of other transmitter systems","volume":"36","author":"Carlsson","year":"1990","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1006\/exnr.2000.7444_RF10","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/0024-3205(90)90346-S","article-title":"The non-competitive NMDA antagonists MK-801 and PCP, as well as the competitive NMDA antagonist SDZ EAA494 (D-CPPene), interact synergistically with clonidine to promote locomotion in monoamine-depleted mice","volume":"47","author":"Carlsson","year":"1990","journal-title":"Life Sci."},{"key":"10.1006\/exnr.2000.7444_RF11","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1001\/archneur.1974.00490350041006","article-title":"Parkinson's disease treated with a suspected dopamine receptor agonist","volume":"30","author":"Chase","year":"1975","journal-title":"Arch. Neurol."},{"key":"10.1006\/exnr.2000.7444_RF12","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/0028-3908(85)90070-X","article-title":"Regional brain uptake of 2-deoxyglucose in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the macaque monkey","volume":"24","author":"Crossman","year":"1985","journal-title":"Neuropharmacology"},{"key":"10.1006\/exnr.2000.7444_RF13","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0300-9629(89)90201-6","article-title":"Neural mechanisms in disorders of movement","volume":"93","author":"Crossman","year":"1989","journal-title":"Comp. Biochem. Physiol."},{"key":"10.1006\/exnr.2000.7444_RF14","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/30748","article-title":"Increased NMDA current and spine density in mice lacking the NMDA receptor subunit NR3A","volume":"393","author":"Das","year":"1998","journal-title":"Nature"},{"key":"10.1006\/exnr.2000.7444_RF15","first-page":"600","article-title":"Similarities and differences between MPTP-induced parkinsonsim and Parkinson's disease. Neuropathologic considerations","volume":"60","author":"Forno","year":"1993","journal-title":"Adv. Neurol"},{"key":"10.1006\/exnr.2000.7444_RF16","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1001\/archneur.1991.00530210109030","article-title":"N-methyl-d-aspartate antagonists in the treatment of Parkinson's disease","volume":"48","author":"Greenamyre","year":"1993","journal-title":"Archs. Neurol."},{"key":"10.1006\/exnr.2000.7444_RF17","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0022-510X(90)90023-G","article-title":"Changes in benzodiazepine and acetylcholine receptors in the globus pallidus in Parkinson's disease","volume":"100","author":"Griffith","year":"1990","journal-title":"J. Neurol. Sci."},{"key":"10.1006\/exnr.2000.7444_RF18","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/ana.410430415","article-title":"Adenosine A2a antagonist: A novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys","volume":"43","author":"Kanda","year":"1998","journal-title":"Ann Neurol"},{"key":"10.1006\/exnr.2000.7444_RF19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0006-8993(96)01192-4","article-title":"Neuroprotective effects of the strychnine-insensitive glycine site NMDA antagonist (+)-HA-966 in an experimental model of Parkinson's disease","volume":"759","author":"Kanthasamy","year":"1997","journal-title":"Brain Res."},{"key":"10.1006\/exnr.2000.7444_RF20","series-title":"Amino Acids: Chemistry, Biology and Medicine","first-page":"269","article-title":"N-methyl-D-aspartate antagonists stimulate locomotor activity in monoamine-depleted rats: Implications for the therapy of Parkinson's disease","author":"Klockgether","year":"1990"},{"key":"10.1006\/exnr.2000.7444_RF21","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/ana.410340413","article-title":"Toward an understanding of the role of glutamate in experimental parkinsonism: Agonist-sensitive sites in the basal ganglia","volume":"34","author":"Klockgether","year":"1993","journal-title":"Ann. Neurol."},{"key":"10.1006\/exnr.2000.7444_RF22","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/00019052-199408000-00012","article-title":"New medical and surgical treatments for Parkinson's disease","volume":"7","author":"Klockgether","year":"1994","journal-title":"Curr. Opin. Neurol."},{"key":"10.1006\/exnr.2000.7444_RF23","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/0896-6273(94)90445-6","article-title":"Mutational analysis of the glycine-binding site of the NMDA receptor: Structural similarity with bacterial amino acid-binding proteins","volume":"12","author":"Kuryatov","year":"1994","journal-title":"Neuron"},{"key":"10.1006\/exnr.2000.7444_RF24","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/358036a0","article-title":"Molecular diversity of the NMDA receptor channel","volume":"358","author":"Kutswada","year":"1992","journal-title":"Nature"},{"key":"10.1006\/exnr.2000.7444_RF25","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1126\/science.6823561","article-title":"Chronic parkinsonism in humans due to a product of meperidine-analog synthesis","volume":"219","author":"Langston","year":"1983","journal-title":"Science"},{"key":"10.1006\/exnr.2000.7444_RF26","first-page":"49","article-title":"MPTP-induced parkinsonism in human and non-human primates\u2014Clinical and experimental aspects","volume":"100","author":"Langston","year":"1984","journal-title":"Acta Neurol. Scand. Suppl."},{"key":"10.1006\/exnr.2000.7444_RF27","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0304-3940(84)90293-3","article-title":"1-Methyl-4-phenylpyridinium ion (MPP+): Identification of a metabolite of MPTP, a toxin selective to the substantia nigra","volume":"48","author":"Langston","year":"1984","journal-title":"Neurosci. Lett."},{"key":"10.1006\/exnr.2000.7444_RF28","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1017\/S0317167100046333","article-title":"Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): Implications for treatment and the pathogenesis of Parkinson's disease","volume":"11","author":"Langston","year":"1984","journal-title":"Can. J. Neurol. Sci."},{"key":"10.1006\/exnr.2000.7444_RF29","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000116349","article-title":"MPTP: Insights into the etiology of Parkinson's disease","volume":"26","author":"Langston","year":"1987","journal-title":"Eur. Neurol."},{"key":"10.1006\/exnr.2000.7444_RF30","doi-asserted-by":"crossref","first-page":"S153","DOI":"10.1212\/WNL.47.6_Suppl_3.153S","article-title":"The etiology of Parkinson's disease with emphasis on the MPTP story","volume":"47","author":"Langston","year":"1996","journal-title":"Neurology"},{"key":"10.1006\/exnr.2000.7444_RF31","article-title":"The NMDA2B antagonist Ro 25-6981 is an anti-parkinsonian agent","volume":"12","author":"Loschmann","year":"1997","journal-title":"Mov. Disord."},{"key":"10.1006\/exnr.2000.7444_RF32","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1006\/exnr.1994.1007","article-title":"On the role of enkephalin cotransmission in the GABAergic striatal efferents to the globus pallidus","volume":"125","author":"Maneuf","year":"1994","journal-title":"Exp. Neurol."},{"key":"10.1006\/exnr.2000.7444_RF33","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1006\/exnr.1996.0075","article-title":"Modulation of GABA transmission by diazoxide and cromakalim in the globus pallidus: Implications for the treatment of Parkinson's disease","volume":"139","author":"Maneuf","year":"1996","journal-title":"Exp. Neurol."},{"key":"10.1006\/exnr.2000.7444_RF34","first-page":"125","article-title":"Tyrosine phosphorylation of NMDA receptors in rat striatum: Effects of 6-OHDA Lesions","volume":"7","author":"Menegoz","year":"1995","journal-title":"Neuroreport"},{"key":"10.1006\/exnr.2000.7444_RF35","series-title":"The Basal Ganglia II","first-page":"415","article-title":"Altered tonic activity of neurons in the globus pallidus and subthalamic nucleus in the primate MPTP model of parkinsonism","author":"Miller","year":"1987"},{"key":"10.1006\/exnr.2000.7444_RF36","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0304-3940(86)90013-3","article-title":"Neural mechanisms mediating 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the monkey: Relative contribution of the striatopallidal and striatonigral pathways are suggested by 2-deoxyglucose uptake","volume":"63","author":"Mitchell","year":"1986","journal-title":"Neurosci. Lett."},{"key":"10.1006\/exnr.2000.7444_RF37","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0306-4522(89)90120-6","article-title":"Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3-6-tetrahydropyridine","volume":"32","author":"Mitchell","year":"1989","journal-title":"Neuroscience"},{"key":"10.1006\/exnr.2000.7444_RF38","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/00008877-199508000-00010","article-title":"Reversal of parkinsonian symptoms by intrastriatal and systemic manipulations of excitatory amino acid and dopamine transmission in the bilateral 6-OHDA lesioned marmoset","volume":"6","author":"Mitchell","year":"1995","journal-title":"Behav. Pharmacol."},{"key":"10.1006\/exnr.2000.7444_RF39","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/syn.890080307","article-title":"Influence of age on N-methyl d-asparate antagonist binding sites in the rat brain studies by in vitro autoradiography","volume":"8","author":"Miyoshi","year":"1991","journal-title":"Synapse"},{"key":"10.1006\/exnr.2000.7444_RF40","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1126\/science.256.5060.1217","article-title":"Heteromeric NMDA receptor: Molecular and functional distinction of subtypes","volume":"256","author":"Monyer","year":"1992","journal-title":"Science"},{"key":"10.1006\/exnr.2000.7444_RF41","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1046\/j.1471-4159.1995.64052043.x","article-title":"NMDA receptor subtype selectivity: Eliprodil, polyamine spider toxins, dextromexthorphan and desipramine selectivity block NMDA evoked acetylcholine but not spermidine release","volume":"64","author":"Nankai","year":"1993","journal-title":"J. Neurochem."},{"key":"10.1006\/exnr.2000.7444_RF42","first-page":"79.5","article-title":"Anti-parkinsonian effect of NR2B-selective NMDA antagonists in animal models of Parkinson's disease: A striatal mechanism of action?","volume":"23","author":"Nash","year":"1997","journal-title":"Soc. Neurosci."},{"key":"10.1006\/exnr.2000.7444_RF43","first-page":"1.129","article-title":"A novel treatment for Parkinson's disease based upon blockade of NR2B-containing NMDA receptors","author":"Nash","year":"1998","journal-title":"5th International Congress of Parkinson's Disease and Movement Disorders"},{"key":"10.1006\/exnr.2000.7444_RF44","first-page":"5.085","article-title":"Do the Anti-Parkinsonian Agents Adenosine A2a Antagonists and NR2B-Selective NMDA Antagonists Share a Common Mechanism of Action?","author":"Nash","year":"1998","journal-title":"5th International Congress of Parkinson's Disease and Movement Disorders"},{"key":"10.1006\/exnr.2000.7444_RF45","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1006\/exnr.1998.6963","article-title":"Anti-parkinsonian actions of blockade of NR2B-containing NMDA receptors in the reserpine-treated rat","volume":"115","author":"Nash","year":"1999","journal-title":"Exp. Neurol."},{"key":"10.1006\/exnr.2000.7444_RF46","unstructured":"Nash, J. E, and, J. M. Brotchie, Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: Intracerebral microinjection studies in the 6-OHDA-lesioned rat, J. Neurosci, Submitted."},{"key":"10.1006\/exnr.2000.7444_RF47","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1046\/j.1471-4159.1994.62051835.x","article-title":"NMDA receptors with different sensitivities to magnesium and ifenprodil control the release of [14C]acetylcholine and [3H]spermidine from rat striatal slices in vitro","volume":"62","author":"Nicolas","year":"1994","journal-title":"J. Neurochem."},{"key":"10.1006\/exnr.2000.7444_RF48","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S0006-8993(98)01049-X","article-title":"Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits: Effect of dopaminergic denervation and l-DOPA administration","volume":"813","author":"Oh","year":"1998","journal-title":"Brain Res."},{"key":"10.1006\/exnr.2000.7444_RF49","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0006-8993(99)01121-X","article-title":"Effect of dopamine denervation and dopamine agonist administration on serine phosphorylation of striatal nmda receptor subunits","volume":"821","author":"Oh","year":"1998","journal-title":"Brain Res."},{"key":"10.1006\/exnr.2000.7444_RF50","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1111\/j.1471-4159.1985.tb07205.x","article-title":"\u03b3-Aminobutyric acid and benzodiazepine receptor changes induced by unilateral 6-hydroxydopamine lesions of the medial forebrain bundle","volume":"45","author":"Pan","year":"1985","journal-title":"J. Neurochem."},{"key":"10.1006\/exnr.2000.7444_RF51","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/mds.870100606","article-title":"Chronic l-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus)","volume":"10","author":"Pearce","year":"1995","journal-title":"Mov. Disord."},{"key":"10.1006\/exnr.2000.7444_RF52","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/mds.870130207","article-title":"De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-DOPA in the MPTP-treated marmoset","volume":"13","author":"Pearce","year":"1998","journal-title":"Mov. Disord."},{"key":"10.1006\/exnr.2000.7444_RF53","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/mds.870020201","article-title":"Young onset Parkinson's disease","volume":"2","author":"Quinn","year":"1987","journal-title":"Mov. Disord."},{"key":"10.1006\/exnr.2000.7444_RF54","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0006-8993(90)90762-Z","article-title":"The role of striatopallidal neurons utilising gamma-aminobutyric acid in the pathophysiology of MPTP-induced parkinsonism in the primate: Evidence from [3H]flunitrazepam autoradiography","volume":"531","author":"Robertson","year":"1990","journal-title":"Brain Res."},{"key":"10.1006\/exnr.2000.7444_RF55","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/0006-8993(91)91545-C","article-title":"Further investigations into the pathophysiology of MPTP-induced parkinsonism in the primate: An intracerebral microdialysis study of \u03b3-aminobutyric acid in the lateral segment of the globus pallidus","volume":"563","author":"Robertson","year":"1991","journal-title":"Brain Res."},{"key":"10.1006\/exnr.2000.7444_RF56","doi-asserted-by":"crossref","first-page":"S175","DOI":"10.1002\/ana.410440726","article-title":"Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: A target for neuroprotection","volume":"44","author":"Rodriguez","year":"1998","journal-title":"Ann. Neurol."},{"key":"10.1006\/exnr.2000.7444_RF57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cne.903430102","article-title":"Organisation of N-methyl-d-asparatate glutamate receptor gene expression in the basal ganglia of the rat","volume":"343","author":"Standaert","year":"1994","journal-title":"J. Comp. Neurol."},{"key":"10.1006\/exnr.2000.7444_RF58","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0014-5793(98)01590-7","article-title":"Identification of a long variant of mRNA encoding the NR3 subunit of the NMDA receptor: Its regional distribution and developmental expression in the rat brain","volume":"441","author":"Sun","year":"1998","journal-title":"FEBS Lett."},{"key":"10.1006\/exnr.2000.7444_RF59","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1600-0404.1989.tb01780.x","article-title":"MPTP-induced parkinsonism as a model for Parkinson's disease","volume":"126","author":"Tetrud","year":"1989","journal-title":"Acta Neurol. Scand. Suppl."},{"key":"10.1006\/exnr.2000.7444_RF60","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/00001756-199211000-00007","article-title":"Elevated NMDA receptors in parkinsonian striatum","volume":"3","author":"Weihmuller","year":"1992","journal-title":"Neuroreport"},{"key":"10.1006\/exnr.2000.7444_RF61","first-page":"851","article-title":"Ifenprodil discriminates subtype of the N-methyl-d-aspartate receptors: Selectivity and mechanisms at recombinant heteromeric receptors","volume":"44","author":"Williams","year":"1993","journal-title":"Mol. Pharmacol."},{"key":"10.1006\/exnr.2000.7444_RF62","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/0028-3908(92)90151-E","article-title":"The competitive NMDA antagonists CGP 40.116 enhances l-DOPA response in MPTP-treated marmosets","volume":"31","author":"Wullner","year":"1992","journal-title":"Neuropharmacology"}],"container-title":["Experimental Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488600974442?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488600974442?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,8]],"date-time":"2019-05-08T23:53:55Z","timestamp":1557359635000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014488600974442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,9]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2000,9]]}},"alternative-id":["S0014488600974442"],"URL":"https:\/\/doi.org\/10.1006\/exnr.2000.7444","relation":{},"ISSN":["0014-4886"],"issn-type":[{"value":"0014-4886","type":"print"}],"subject":[],"published":{"date-parts":[[2000,9]]}}}